{"brief_title": "Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer", "brief_summary": "Determine tumor response rate and time to disease progression, survival and safety in total populations.", "detailed_description": "To determine the tumor response rate and time to disease progression, survival and safety in the EGFR-positive, EGFR-negative and total populations.", "condition": "Non-Small-Cell Lung Cancer", "intervention_type": "Biological", "intervention_name": "Cetuximab", "description": "Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).", "arm_group_label": "1", "other_name": "Erbitux", "criteria": "Inclusion Criteria 1. Subjects with recurrent or progressive NSCLC with either present or prior histologic confirmation or pathologic confirmation of NSCLC 2. Subjects receiving 1 or more prior chemotherapy regimens for the treatment of recurrent/metastatic disease, including at least 1 platinum-based combination 3. Unidimensionally measurable NSCLC 4. Subjects with tumor tissue available for EGFR assessment 5. ECOG performance status of 0 or 1 6. Subjects with asymptomatic brain metastasis were eligible; however, they must have completed radiotherapy/radiosurgery at least 3 weeks prior to enrollment and have been off steroids Exclusion Criteria 1. Women of childbearing potential who were unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study. Male subjects must also have agreed to use effective contraception 2. Women of childbearing potential using a prohibited contraceptive method 3. Women who were pregnant or breastfeeding 4. Women with a positive pregnancy test on enrollment or prior to study drug administration.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00063388.xml"}